No abstract

2؉ , independently of CaM, inhibited isoproterenol-stimulated AC. Data suggest that agonist augmentation of stimulated cAMP levels is due to activation of AC8 in mouse parotid acini, and strongly support a role for AC5/6 in the inhibition of stimulated cAMP levels.To date, 10 different ACs, 1 each with distinct regulatory properties, have been cloned; their existence suggests that they may be differentially regulated. The enzymes exhibit type specific stimulatory and inhibitory regulation by G-protein ␣ and ␤␥ subunits, Ca 2ϩ , CaM, forskolin, P-site inhibitors, protein kinases A and C (PKC) (2-6), and calcineurin (7) entry plays an important role in promoting AC synthesis. These data, combined with findings that AC8 is expressed in mouse parotid acini (1) and that Ca 2ϩ /CaM stimulates AC and augments the effects of forskolin on cyclase activity in membrane fractions and intact cells (21,22), are consistent with results obtained in HEK 293 cells expressing AC8 (8, 11).Interpretation of the mechanism(s) involved in the cross-talk that occurs between the Ca 2ϩ and cAMP signaling pathways in cells is complex and requires not only identification of AC subtypes expressed, but also tools that provide definitive answers as to regulation of AC synthesis in specific cell types. Thus, the goal of the present study was to determine the involvement of AC8 in agonist-induced augmentation of stimulated cAMP levels in mouse parotid acini by examining the effects of carbachol and the microsomal Ca 2ϩ -ATPase inhibitor, thapsigargin, on isoproterenol-induced cAMP accumulation in acini from AC8-KO mice. Our data show that carbachol and thapsigargin augmented stimulated cAMP accumulation in acini from wild type (WT) mice as previously reported (1), whereas these agents not only prevented augmentation, but inhibited isoproterenol-induced cAMP accumulation in AC8-KO mice. Augmentation of stimulated cAMP accumulation, however, was not affected in acini from AC1-KO mice. Agonist-induced inhibition of stimulated cAMP accumulation was reversed in a nominally Ca 2ϩ -free buffer and in the presence of lanthanum (La 3ϩ ), but not by KN-62, an inhibitor of CaM kinase, or by the CaM antagonist, calmidazolium. Studies with isolated parotid membranes revealed that Ca 2ϩ , independently of CaM, inhibits AC activity in a concentration-dependent manner, consistent with the expression of the Ca 2ϩ -inhibited AC5/6 isoforms in parotid gland. Results demonstrate that capacitative Ca 2ϩ entry is associated with the activation of AC8 in mouse parotid acini and support an involvement of AC5/6 in the inhibition of cAMP synthesis.

Muscarinic receptor interaction leading to augmentation of isoproterenol-stimulated cAMP accumulation in mouse parotid acini involves Ca2+ (28). The effectiveness of capacitative Ca2+entry and intracellular Ca2+release on this response was determined in time course studies by using three independent tools to manipulate the free intracellular Ca2+ concentration: the muscarinic agonist carbachol, thapsigargin, and ionomycin. Time course studies revealed that Ca2+ release from intracellular stores by carbachol produced an early rapid increase (0.25–0.5 min) in stimulated cAMP levels, whereas capacitative Ca2+ entry resulted in a sustained increase in stimulated cAMP levels that was blocked by La3+. Capacitative Ca2+ entry, alone, was involved in thapsigargin and ionomycin augmentation of stimulated cAMP accumulation. The inability of phosphodiesterase inhibitors, 3-isobutyl-1-methylxanthine and milrinone, to prevent agonist augmentation of cAMP levels, as well as the finding that the type VIII adenylyl cyclase (ACVIII) is expressed in parotid acini, suggests that capacitative Ca2+ entry augments stimulated cAMP accumulation, at least in part, via activation of this adenylyl cyclase isoenzyme.

No abstract

Immunoprecipitation of muscarinic receptors from mouse parotid membranes by specific subtype antisera showed that M3 and M1 receptors represented 75 and 15% of the total number of precipitable receptors, respectively. [N-methyl-3H]methylscopolamine (NMS) labeled a single class of high-affinity binding sites in membranes from parotid glands with a dissociation constant of 0.67 +/- 0.02 nM and a maximum binding capacity of 176 +/- 15 fmol/mg protein. Competition curves for NMS, atropine, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) and para-fluoro-hexahydro-sila-difenidol fit best to a one-site binding model, whereas pirenzepine and methoctramine fit best to a two-site binding model, indicating 76-90% M3 receptors. Results from the use of pirenzepine indicated that the second mouse parotid receptor subtype, unlike that of the submandibular gland, has atypical characteristics for an M1 receptor. The rank order of potency of muscarinic antagonists in inhibiting phosphoinositide turnover and biphasic effects of carbachol on isoproterenol-stimulated adenosine 3',5'-cyclic monophosphate (cAMP) accumulation was atropine > or = 4-DAMP >> pirenzepine > AF-DX 116. A specific M1 antagonist, m1-toxin, had no effect on carbachol augmentation or inhibition of isoproterenol responses. Results suggest that M3 receptors couple to both augmentation and inhibition of stimulated cAMP levels.